A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
Status:
Completed
Trial end date:
2017-11-07
Target enrollment:
Participant gender:
Summary
The present study will be conducted to evaluate the efficacy and safety of AMG531 and to
determine the recommended initial dose of AMG531 on the basis of its efficacy and safety when
it is administered subcutaneously (SC) to the Aplastic Anemia (AA) patients with
immunosuppressive-therapy refractory thrombocytopenia and also to assess the pharmacokinetics
of this product. Its efficacy and safety during the extension period beyond one year will
also be evaluated.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Korea Co., Ltd. Kyowa Kirin Korea Co., Ltd.